Use of immunological markers and continuous-time Markov models to estimate progression of HIV infection in homosexual men

被引:38
作者
Hendriks, JCM
Satten, GA
Longini, IM
vanDruten, HAM
Schellekens, PTA
Coutinho, RA
vanGriensven, GJP
机构
[1] MUNICIPAL HLTH SERV,DEPT PUBL HLTH,AMSTERDAM,NETHERLANDS
[2] EMORY UNIV,SCH PUBL HLTH,ATLANTA,GA
[3] EMORY UNIV,CTR DIS CONTROL & PREVENT,ATLANTA,GA 30322
[4] UNIV AMSTERDAM,NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,AMSTERDAM,NETHERLANDS
关键词
immunological marker; CD4; counts; anti-CD3; reactivity; HIV disease progression; Markov model; incubation period distribution; homosexual men;
D O I
10.1097/00002030-199606000-00011
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: We used continuous-time Markov models based on CD4 cell counts and anti-CD3 reactivity (i.e., measure for T-cell quality) to study the progression of HIV infection in a cohort study of homosexual men in Amsterdam. We also compared the effectiveness of anti-CD3 reactivity as a marker for disease progression with that of CD4 cell counts. Methods: We used data from 467 men (6905 visits) with visits at 3-month intervals between October 1984 and March 1993. To account for measurement error and short time-scale variability, the immunological stage at each visit was determined using a kernel smoother on log-transformed data from each individual. The Markov model had six marker-defined stages and a seventh stage for clinical AIDS. The initial stage-occupation probabilities for seroconverters were used to estimate the incubation time from infection to AIDS. Confidence intervals were calculated using the bootstrap method to account for the effect of smoothing on the variability of our estimates. Results: The CD4 staging scheme estimated the median time from seroconversion to AIDS at 8.3 years [95% confidence interval (CI), 8.1-8.6], and a similar estimate was obtained with the anti-CD3 staging model. The CD4 model predicts that 10.2% (95% CI, 9.9-13.1) will remain AIDS-free 15 years after seroconversion. The mean number of stages visited before AIDS is lower with the CD4 model (7.4; 95% CI, 7.2-7.7) than with the anti-CD3 model (11.3; 95% Cl, 10.8-12.0), implying that anti-CD3 predicts progression less well than CD4 cell count. Conclusions: CD4 lymphocyte counts and anti-CD3 reactivity are each associated with an increased hazard for progression to AIDS. Therefore, men in different CD4-stages (anti-CD3 stages) follow different incubation period distributions to AIDS. However, anti-CD3 predicts progression less well than CD4 cell count. Staged time-continuous Markov models are useful to study immunological markers for HIV disease progression.
引用
收藏
页码:649 / 656
页数:8
相关论文
共 25 条
  • [1] BASS HZ, 1992, J ACQ IMMUN DEF SYND, V5, P890
  • [2] WHOLE-BLOOD LYMPHOCYTE-CULTURES
    BLOEMENA, E
    ROOS, MTL
    VANHEIJST, JLAM
    VOSSEN, JMJJ
    SCHELLEKENS, PTA
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1989, 122 (02) : 161 - 167
  • [3] CHIANG C, 1980, INTRO STOCHASTIC PRO
  • [4] ZIDOVUDINE IN PERSONS WITH ASYMPTOMATIC HIV-INFECTION AND CD4+ CELL COUNTS GREATER-THAN 400 PER CUBIC MILLIMETER
    COOPER, DA
    GATELL, JM
    KROON, S
    CLUMECK, N
    MILLARD, J
    GOEBEL, FD
    BRUUN, JN
    STINGL, G
    MELVILLE, RL
    GONZALEZLAHOZ, J
    STEVENS, JW
    FIDDIAN, AP
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (05) : 297 - 303
  • [5] 5-YEAR PROSPECTIVE-STUDY OF HIV-INFECTION IN THE EDINBURGH HEMOPHILIAC COHORT
    CUTHBERT, RJG
    LUDLAM, CA
    TUCKER, J
    STEEL, CM
    BEATSON, D
    REBUS, S
    PEUTHERER, JF
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1990, 301 (6758): : 956 - 961
  • [6] DEWOLF F, 1988, J INFECT DIS, V158, P615, DOI 10.1093/infdis/158.3.615
  • [7] Efron B., 1982, SOC IND APPL MATH CB, V38
  • [8] Hardle W., 1990, APPL NONPARAMETRIC R, DOI DOI 10.1017/CCOL0521382483
  • [9] THE TREATMENT-FREE INCUBATION PERIOD OF AIDS IN A COHORT OF HOMOSEXUAL MEN
    HENDRIKS, JCM
    MEDLEY, GF
    VANGRIENSVEN, GJP
    COUTINHO, RA
    HEISTERKAMP, SH
    VANDRUTEN, HAM
    [J]. AIDS, 1993, 7 (02) : 231 - 239
  • [10] HOOVER DR, 1992, J ACQ IMMUN DEF SYND, V5, P794